Access : Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update : Clinical Pharmacology & Therapeutics

Access : Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update : Clinical Pharmacology & Therapeutics

CPIC Update

Clinical Pharmacology & Therapeutics (17 January 2013) | doi:10.1038/clpt.2013.4

• Article Tools

• Search Pubmed for

  • M V Relling
  • E E Gardner
  • W J Sandborn
  • K Schmiegelow
  • C-H Pui
  • S W Yee
  • more authors of this article

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

M V Relling, E E Gardner, W J Sandborn, K Schmiegelow, C-H Pui, S W Yee, C M Stein, M Carrillo, W E Evans, J K Hicks, M Schwab and T E Klein

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Methyltransferase Genotype and Thiopurine Dosing was originally published in March 2011. We reviewed recent literature and concluded that although relevant new evidence has been generated, none of the evidence would change the primary dosing recommendations in the original guideline; therefore, the original publication remains clinically current. Up-to-date information on thiopurine methyltransferase (TPMT) gene alleles and nomenclature can be found at PharmGKB (http://www.pharmgkb.org).